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ABSTRACT 
PURPOSE: PMTCT interventions, especially initiation of Highly active antiretroviral therapy (HAART) has modified the 
natural history of HIV infection by reducing both peripartal and neonatal HIV infections, but the pattern of the  immunologic 
responses of these pregnant women to HAART remains speculative. It is hoped from this study, to describe the pattern of 
immunologic response of naïve, HIV positive pregnant women on their first initiation on HAART. 
METHODS: This study described the pattern of CD4 changes observed in freshly diagnosed 126 HIV positive pregnant 
women, stratified into the trimesters of pregnancy and commenced on HAART (Zidovudine, Lamivudine and Nevirapine) for 
a period of 2 months in pregnancy. CD4 counts were determined at point of recruitment and monthly thereafter using a 
Parteccytometer counter (Cyflow(R)). Neonatal outcome was also described. 
RESULTS: Our findings suggest better immunologic response and fewer neonatal infectionsin group of naïve women 
initiated on HAART while in the first 26 weeks of pregnancy and lesser response in those commenced in the third trimester 
of pregnancy.  
CONCLUSION: Concerted efforts should be directed towards the initiation of HAART prophylaxis before end of 2nd 
trimester of pregnancy. 
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INTRODUCTION 
It is well known that the introduction and 
widespread use of highly active antiretroviral 
therapy (HAART) has modified the natural history 
of HIV infection.Significantly, PMTCT practices 
remain very effective public healthinterventionsin 
improving maternal health, as well as reducing both 
peripartal and neonatal HIV infections [1, 2]. While, 
attempts had been made in general HIV positive 
patients to characterise both immunologic and 
virologic responses in patients on HAART in 
developed countries, such attentions have not been 
focussed on HIV positive pregnant population, more 
especially, in our environment with high HIV 
infection burden. We found no record in our 
environment of any description of the pattern of 
immunologic responses of pregnant HIV positive 
women on antiretroviral drugs. Thus it becomes 
highly imperative for such, considering the hitherto 
immunologic changes expected of normal 
pregnancy. This study thus attempt an assessment of 
the pattern of immunologic (CD4) changes in naïve 
HIV positive pregnant women, in the first two 
months of commencing HAART, with a view to  
 
possibly postulate CD4 response rate and 
recommend the ideal time to initiate HAARTin HIV 
positive pregnant patients. 
METHODOLOGY 
Patients with double positive parallel rapid test 
results at EGA 12 - 28 weeks at LAUTECH Teaching 
Hospital, Osogbo, Nigeria in the year 2008/2009 
were prospectively enrolled into the study and 
stratified into the 3groups by the trimesters of 
pregnancy. Institutional Ethical approval was 
obtained for the study. All patients recruited gave 
consent and had venous blood samples collected into 
EDTA bottle for CD4 count (cells/µl) at point of 
recruitment and monthly thereafter using a Partec 
cytometer counter (Cyflow(R)), among other pre-
requisite investigations for monitoring in ARV 
therapy. Each patient was prescribed combination of 
Highly Active Antiretroviral Therapy (HAART) of 
tablets of Zidovudine 300mg twice daily, 
Lamivudine 150mg twice daily and 
Nevirapine200mg daily first two weeks, thereafter 
200mg twice daily according to the National 
guideline1. Patients with Haemoglobin level <8g/dl, 
concomitant Hepatitis C or any opportunistic 





from the study. Biochemical monitoring was as 
prescribed in the National guideline for PMTCT 
(Nigeria). Data obtained were analysed for 
descriptive statistics using SPSS 17 statistical 
package, percentage difference of mean of the CD4 
counts, stratified by trimesters of pregnancy 
determined and ANOVA for difference of means 
between groups at initiation of HAART and at 4th 
and 8th week respectively. 
RESULTS 
A total of 126 patients were recruited over the 2 
years period. The overall mean age (Years), Parity 
and EGA (Weeks) was 29.73 + 4.42, 1.52 + 1.41 and 
19.96 + 4.20 respectively.  
 
TABLE I: DEMOGRAPHY OF PATIENTS 
 N Minimum Maximum Mean Std. Deviation 
AGE (Years) 126 20.00 40.00 29.73 4.42 
PARITY 126 .00 5.00 1.52 1.41 
EGA (Weeks) 126 12.00 28.00 19.96 4.20 
      
 
In the 1st trimester group Mean0 CD4 = 408.75 
cells/µL (223.70), C.I = 221.73, 595.77, Mean1 = 544 
cells/µL (224.90), C.I = 355.98, 732.02, and Mean2= 
626.63 cells/µL (247.27), C.I = 419.90, 833.00. The 
counts in the 2nd trimester group are, *Mean0= 
367.07 cells/µL (202.67), C.I = 202.67, 328.95, *Mean1 
= 489.41 cells/µL (173.23), C.I = 456.82 – 521.99, 
*Mean2= 560.43 cells/µL (154.56), C.I = 531.36, 
589.51. The 3rd trimester group’s parameters are as 
follows: **Mean0= 540.14 cells/µL (188.86), C.I = 
365.48, 714.81, **Mean1 = 607.14 cells/µL (164.22), C.I 
= 164.22, 455.27, **Mean2 = 650.26 cells/µL (163.85), 
C.I = 498.75, 801.82.  The overall mean CD4 change 
in the 2 months of study in the three trimesters 
groups are 217, 192.93 and 110.12cells/µL (P = 0.088, 
0.179, 0.217) respectively, while the percentages 
differences of Mean of the CD4 counts in between 
points of evaluation for each trimester are: 33.09% 
& 15.19% (1st trimester), 33.33% & 14.51% (2nd 
trimester) and 12.38% & 7.13% (3rd trimesters) 
respectively. 
 
TABLE II: DISTRIBUTION OF PATIENTS BY TRIMESTERS OF PREGNANCY 






1st Trimester  28.750 (4.683) 0 – 2 (1) 12.750 (0.463) 
2nd Trimester 29.982 (4.464) 0 – 5 (1) 20.027 (3.602) 
3rd Trimester  26.857 (2.340) 0 – 4 (3) 27.143 (0.378) 
 
 
TABLE III: AVERAGE CD4 COUNTS OF PATIENTS AT RECRUITMENT AND MONTHLY 
Trimesters Mean CD40 (C.I) cells/µL Mean CD41 (C.I) cells/µL Mean CD42 (C.I) cells/µL 
First 408.75 (221.73, 595.77) 544.00 (355.98, 732.02) 626.63 (419.90, 833.00) 
Second 367.07 (202.67, 328.95) 489.41 (456.82, 521.99) 560.43 (531.36, 589.51) 
Third 540.14 (365.48, 714.81) 607.00 (164.22, 455.27) 650.26 (498.75, 801.82) 
P-value 0.088 0.179 0.217 
 
DISCUSSION 
Highly Active Antiretroviral Therapy (HAART) -
typically composed of 3 antiretroviral agents from 2 
drug classes - has substantially reduced MTCT rates 
through successful suppression of HIV RNA load[1, 
2]. This fact has been established in many 
collaborative studies and therefore formed the basis 
of the recommendation for the HAART prophylaxis 
in HIV positive pregnant women, irrespective of the 
CD4 count levels[1, 3, 4]. It is therefore a well-known  
 
fact that responses to antiretroviral drugs (ARVs) are 
both virologic (HIV RNA load) and immunologic 
(CD4 count). 
In this study we described the pattern of CD4 
changes observed in freshly diagnosed HIV positive 
pregnant women,across the trimesters, in our 





(Zidovudine, Lamivudine and Nevirapine) for a 
period of 2 months in pregnancy.  
Our findings showednumerically, but statistically 
insignificant, higher immunologic response in group 
of naïve women initiated on HAART while in the 
first 26 weeks of pregnancyand lesser response in 
those commenced in the third trimester of pregnancy 
(Table IV).  
 
TABLE IV: CALCULATED PERCENTAGE DIFFERENCE OF MEANS BY TRIMESTERS OF PREGNANCY 
Trimesters % Difference of Means1 
( At 0 – 4th week) 
% Difference of Means2 
(4th  - 8th  week) 
First Trimester 33.09% 15.19% 
Second Trimester 33.33% 14.51% 
Third Trimester 12.38% 7.13% 
Key: 
CD40  - CD4 at commencement of HAART 
CD41 - CD4 at 4 weeks of commencement of HAART 
CD42 - CD4 at 8 weeks of commencement of HAART 
C.I - 95% Confidence Interval 
Difference of Means1 - Difference between initiation & 4 weeks of HAART 
Difference of Means2 - Difference between 4th weekand 8th week of HAART 
 
The might not be un-related to the adaptive 
immunology of pregnancy, whereby, elevated levels 
of progesterone and estrogen, greatest during the 
first half of pregnancy, lead to an increase in CD4+ , 
CD25+ regulatory T cells and tolerance to 
alloantigens such as fetal antigens[5, 6]. The effect of 
pregnancy on regulatory T cells could possibly lead 
to a better virologic response to HAART in women 
first experiencing HAART during pregnancy. If this 
be the case, we can at least exploit this natural 
advantage and strive to initiate HAART in HIV 
positive pregnant women in the first half of 
pregnancy at the latest. It is incontrovertible, that 
opportunistic infection, AIDS related complications 
and consequently risks of mother-to-child infections 
are much less with adequate defence confer by good 
CD4 [7]. However, some other studies, comparing 
CD4 changes in HIV-1 positive pregnant women, 
had reported that women have lower CD4 cell 
counts changes during pregnancy than in the 
postpartum period [8].Few studies have actually 
described CD4 changes in pregnant women on 
HAART and even in those studies, it was 
comparison of the changes in pregnancy with the 
postpartum period [9] 
In our patients’ population, the mean CD4 counts of 
the 3rd trimester group was the highest at diagnosis 
and enrolment, but only improved by percentage 
difference of 12.38% and 7.13% in the two 
subsequent 4 weekly interval, compared with 33.09% 
and 15.19% (1st trimester group) and 33.33% and 
14.51% (2nd trimester group) respectively. However, 
a consistent finding across the groups is progressive 
decline in increment in means as the weeks increase 
(Table IV). 
Although we controlled and excluded important 
baseline characteristics that are associated with 
immune recovery ( illicitdrug use [10] and hepatitis 
C virus co-infection[11]), other factors such as 
baseline CD4+ lymphocyte count, duration of HIV 
infection and HIV-1 viral load, CD4+ lymphocyte 
count nadir [12] could not be excluded. Some other 
inherent limitations preclude causal inferences from 
this study. First, being that the study is observational 
in nature. Also, the patients are not evenly 
distributed across groups, third is the time limit 
conferred by the duration of pregnancyand lastly, 
perhaps most important is the inability, due to 
limited resources in our setting, to concurrently 
assess the viral load and correlate with the CD4 
count. It must however be stated that WHO and 
National guideline, due to this resources limitation 
recommended CD4 counts for response monitoring 
in HIV patient on ARV[13, 1]. 
In this study, we recorded 2 perinatal deaths and 4 
HIV neonatal infections by the 6th month of follow-
up (vertical transmission rate of 3.17%), 3 of which 
occurred in the women enrolled in the 3rd trimester 
and 1 in the 2nd trimester, while both perinatal 
deaths were due to severe asphyxia. All the women 
in whom neonatal infections were recorded 
breastfed their babies and were continuing 
prophylactic HAART. 
It is however, noteworthy, that possibly because of 
exclusion of other co-infections – HCV and other 
opportunistic infections, as well as drug and alcohol 
abuse, most of the patients had above 400 CD4 from 





With the above noted, this study found a better 
immunologic response among HIV positive, ARV 
naïve women who started HAART during the first 
26 weeks of pregnancy compared to women who 
started HAART in the last 13 weeks, though a causal 
relationship could not be established due to the low 
power of this study. However, in our opinion, this 
might pose great clinical challenges in our 
environment where late antenatal care booking is the 
norm. At the moment, HAART’s response 
monitoringin our environment is limited to 
Immunologic parameter (CD4 count) only, with just 
very few research centres having the capacity to 
undertake virologic monitoring. 
It is hereby summated that there might bebetter 
immunological response in ARV naïve HIV positive 
pregnant women when commenced on HAART in 
the first 26 weeks of pregnancy, as progressive 
decline in CD4 increase was observed as the 
pregnancy advanced across the trimester, with the 
least immunological response and more neonatal 
infection observed in 3rd trimester group. Public 
health enlightenment should utilize this information 
and efforts should be directed to the initiation of 
HAART prophylaxis before end of 2nd trimester of 
pregnancy.Larger studies with concurrent viral load 
assessment are however recommended to further 
explore causal relationship of these factors.   
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